PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data.
Solish N, Ascher B, Avelar RL, Bertucci V, Bodokh I, Carruthers J, Cartier H, Delmar H, Denfeld R, Heckmann M, Hedén P, Hilton S, Inglefield C, Ogilvie P, Rzany BJ, Sattler G, Sebastian M, Swift A, Trévidic P.
Solish N, et al.
Aesthet Surg J. 2022 Dec 14;42(12):1460-1469. doi: 10.1093/asj/sjac210.
Aesthet Surg J. 2022.
PMID: 35922149
Free PMC article.
Clinical Trial.
METHODS: Post-hoc analyses were performed on the subpopulation of male patients treated with either a single dose of 20 U prabotulinumtoxinA (n = 25) or 20 U onabotulinumtoxinA (n = 31) in the EVB-003 Phase III glabellar line clinical study. ...
METHODS: Post-hoc analyses were performed on the subpopulation of male patients treated with either a single dose of 20 U prabotulinumtoxinA …